- Published on
Infectious disease and microbiology – Pelvic inflammatory disease
Pelvic inflammatory disease (PID) is a broad term describing infection and inflammation of the upper female genital tract, including conditions such as endometritis, salpingitis, oophoritis, tubo-ovarian abscess, and pelvic peritonitis. It typically presents with lower abdominal or pelvic pain, often accompanied by abnormal vaginal discharge, dyspareunia, dysuria, or abnormal uterine bleeding.
PID is a major public health concern, with nearly 1 million cases annually in the United States, and remains one of the most common gynecologic emergencies, especially among adolescents and young women. Risk factors include multiple sexual partners, unprotected intercourse, prior episodes of PID, and recent intrauterine device (IUD) insertion, particularly within the first few weeks. Bacterial vaginosis is frequently associated but is not a sole cause.
The condition is usually polymicrobial, with the most common causative organisms being Neisseria gonorrhoeae and Chlamydia trachomatis, often in combination with anaerobic bacteria such as Bacteroides and Peptostreptococcus. Other organisms like Gardnerella vaginalis, enteric gram-negative rods, streptococci, and Mycoplasma hominis may also be involved. In rare cases, Actinomyces (especially in IUD users) or Mycobacterium tuberculosis (in developing countries) may be responsible.
Clinically, patients often report bilateral, dull pelvic pain of subacute onset, along with abnormal vaginal discharge and menstrual irregularities. Additional symptoms may include nausea, vomiting, or even right upper quadrant pain in cases of Fitz-Hugh–Curtis syndrome (perihepatitis). On examination, cervical motion tenderness, uterine tenderness, and adnexal tenderness are key findings, often accompanied by fever and mucopurulent cervical discharge.
Diagnosis is largely clinical, supported by laboratory tests such as CBC, inflammatory markers (ESR, CRP), and nucleic acid amplification tests for gonorrhea and chlamydia. Pregnancy testing is essential to exclude ectopic pregnancy. Imaging with transvaginal ultrasound or CT/MRI may be used when the diagnosis is uncertain or complications like tubo-ovarian abscess are suspected. In difficult cases, laparoscopy can provide definitive diagnosis.
Treatment requires prompt broad-spectrum antibiotic therapy targeting likely pathogens. Outpatient regimens typically include a third-generation cephalosporin (e.g., ceftriaxone) plus doxycycline, often with metronidazole for anaerobic coverage. More severe cases require hospitalization and intravenous therapy, such as cefoxitin or cefotetan plus doxycycline, or clindamycin with gentamicin. Therapy is usually continued for 14 days, and clinical improvement is expected within 72 hours.
Surgical intervention may be necessary for large or refractory tubo-ovarian abscesses. Management also includes evaluation and treatment of sexual partners to prevent reinfection. Preventive strategies focus on safe-sex practices, condom use, limiting sexual partners, and prompt treatment of sexually transmitted infections.
The prognosis is generally good with early treatment, but delayed or inadequate therapy can lead to serious complications. These include infertility (increasing with repeated episodes), ectopic pregnancy, chronic pelvic pain, and, rarely, death due to rupture of a tubo-ovarian abscess and generalized peritonitis. Early recognition and appropriate management are therefore critical to reducing long-term morbidity.
Pelvic inflammatory disease (PID) is a broad term describing infection and inflammation of the upper female genital tract, including conditions such as endometritis, salpingitis, oophoritis, tubo-ovarian abscess, and pelvic peritonitis. It typically presents with lower abdominal or pelvic pain, often accompanied by abnormal vaginal discharge, dyspareunia, dysuria, or abnormal uterine bleeding.
PID is a major public health concern, with nearly 1 million cases annually in the United States, and remains one of the most common gynecologic emergencies, especially among adolescents and young women. Risk factors include multiple sexual partners, unprotected intercourse, prior episodes of PID, and recent intrauterine device (IUD) insertion, particularly within the first few weeks. Bacterial vaginosis is frequently associated but is not a sole cause.
The condition is usually polymicrobial, with the most common causative organisms being Neisseria gonorrhoeae and Chlamydia trachomatis, often in combination with anaerobic bacteria such as Bacteroides and Peptostreptococcus. Other organisms like Gardnerella vaginalis, enteric gram-negative rods, streptococci, and Mycoplasma hominis may also be involved. In rare cases, Actinomyces (especially in IUD users) or Mycobacterium tuberculosis (in developing countries) may be responsible.
Clinically, patients often report bilateral, dull pelvic pain of subacute onset, along with abnormal vaginal discharge and menstrual irregularities. Additional symptoms may include nausea, vomiting, or even right upper quadrant pain in cases of Fitz-Hugh–Curtis syndrome (perihepatitis). On examination, cervical motion tenderness, uterine tenderness, and adnexal tenderness are key findings, often accompanied by fever and mucopurulent cervical discharge.
Diagnosis is largely clinical, supported by laboratory tests such as CBC, inflammatory markers (ESR, CRP), and nucleic acid amplification tests for gonorrhea and chlamydia. Pregnancy testing is essential to exclude ectopic pregnancy. Imaging with transvaginal ultrasound or CT/MRI may be used when the diagnosis is uncertain or complications like tubo-ovarian abscess are suspected. In difficult cases, laparoscopy can provide definitive diagnosis.
Treatment requires prompt broad-spectrum antibiotic therapy targeting likely pathogens. Outpatient regimens typically include a third-generation cephalosporin (e.g., ceftriaxone) plus doxycycline, often with metronidazole for anaerobic coverage. More severe cases require hospitalization and intravenous therapy, such as cefoxitin or cefotetan plus doxycycline, or clindamycin with gentamicin. Therapy is usually continued for 14 days, and clinical improvement is expected within 72 hours.
Surgical intervention may be necessary for large or refractory tubo-ovarian abscesses. Management also includes evaluation and treatment of sexual partners to prevent reinfection. Preventive strategies focus on safe-sex practices, condom use, limiting sexual partners, and prompt treatment of sexually transmitted infections.
The prognosis is generally good with early treatment, but delayed or inadequate therapy can lead to serious complications. These include infertility (increasing with repeated episodes), ectopic pregnancy, chronic pelvic pain, and, rarely, death due to rupture of a tubo-ovarian abscess and generalized peritonitis. Early recognition and appropriate management are therefore critical to reducing long-term morbidity.
0 Comments
